No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients by Stelma, F, van der Ree, M, Sinnige, M, Brown, A, Swadling, L, Willemse, S, van der Valk, M, de Vree, J, Klenerman, P, Barnes, E, Kootstra, N, Reesink, H

A single dose of anti-miR-122, RG-101, in CHC patients results in NK cell normalization with no effect on HCV-specific CD8+ T cell function by Stelma, F, van der Ree, M, Sinnige, M, Brown, A, Swadling, L, de Vree, J, Willemse, S, van der Valk, M, Grint, P, Neben, S, Klenerman, P, Barnes, E, Kootstra, N, Reesink, H

Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101. by Stelma, F, van der Ree, M, Sinnige, M, Brown, A, Swadling, L, de Vree, J, Willemse, S, van der Valk, M, Grint, P, Neben, S, Klenerman, P, Barnes, E, Kootstra, N, Reesink, H

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing by van der Ree, M, Stelma, F, Willemse, S, Brown, A, Swadling, L, van der Valk, M, Sinnige, M, van Nuenen, A, de Vree, J, Klenerman, P, Barnes, E, Kootstra, N, Reesink, H